Type 2 Diabetes

Cornerstone Blog

In the News: Metabolic Disease, Concussion in Young Children

Published on

Jul 5, 2024

In the News: Metabolic Disease, Concussion in Young Children

CHOP experts look to improve young concussion patients’ outcomes and develop an image-based classification tool for retinopathy of prematurity.

Childhood Type 2 Diabetes Study of a Single Dose of "LY3209590" a Weekly Insulin Injection

The aim of this study is to evaluate safety, and tolerability of insulin LY3209590 following a single dose given to children with type 2 diabetes mellitus (T2DM).

Cornerstone Blog

Mitochondrial Disease, ALL, Type 2 Diabetes, Sleep Apnea

Published on

Sep 16, 2022

This week’s In the News highlights research on mitochondrial disease, acute lymphoblastic leukemia, type 2 diabetes, and sleep apnea.

Center for Spatial and Functional Genomics

The Center for Spatial and Functional Genomics is focused on uncovering the correct functional context of variants identified by genome-wide association studies in order to translate these discoveries into meaningful benefits for pediatric care.

Spatial and Functional Genomics Research Affinity Group

Uncovering the correct functional context of genetic variants to translate genome-wide association studies into meaningful benefits for pediatric care.

Cornerstone Blog

COVID Breathalyzer, Distinguished Career Awardee, Kids’ COVID Vaccine, Youth-Onset Type 2 Diabetes, Mental Health and Greenspace

Published on

Aug 6, 2021

This week’s research news features Dr. Audrey Odom John and her discovery of six breath compounds that could lead to a COVID breathalyzer for kids.

Ertugliflozin for Children and Adolescents with Type 2 Diabetes

You are invited to take part in a voluntary research trial because you have type 2 diabetes and are between the ages of 10 and 17 years.

Roizen Laboratory

The Roizen Lab aims to understand non-calciometabolic vitamin D effects and to use this understanding to design new therapies for common diseases like sarcopenia and obesity.

Canagliflozin in Children with Type 2 Diabetes

The goal of this study is to investigate the efficacy and safety of Canagliflozin (which is experimental) in children and adolescents ages 10 to 18 years old with Type 2 diabetes and poor control (i.e., an HbA1c of 6.5% to 10.5%)

Steven M. Willi, MD

Dr. Willi's research focuses on therapeutics for type 1 and type 2 diabetes and he has performed a number of physiologic studies in the etiology and characterization of diabetes in children. His current studies include trials on the delay of progression of type 1 diabetes and a multicenter trial to examine the optimal therapeutics for type 2 diabetes in children.

E-mail:

willi [at] chop.edu